Overview
Pyronaridine has been investigated for the treatment of Malaria.
Indication
本品用于治疗脑型、凶险型及耐氯喹虫珠所致的恶性疟,也用于治疗间日疟。
Associated Conditions
- Acute Falciparum Malaria
- Acute Malaria caused by plasmodium vivax
Clinical Trials
Title | Posted | Study ID | Phase | Status | Sponsor |
---|---|---|---|---|---|
2023/08/03 | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | ||
2023/01/18 | Phase 2 | Completed | Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany | ||
2022/07/01 | Phase 1 | Not yet recruiting | |||
2022/03/22 | Phase 2 | UNKNOWN | |||
2022/03/18 | Phase 1 | Completed | Medicines for Malaria Venture | ||
2021/12/16 | Phase 1 | Completed | Medicines for Malaria Venture | ||
2020/04/30 | Phase 3 | Terminated | Medicines for Malaria Venture | ||
2019/08/08 | Phase 2 | Completed | |||
2019/01/24 | Phase 2 | UNKNOWN | |||
2017/06/28 | Phase 4 | Completed |
FDA Drug Approvals
Approved Product | Manufacturer | NDC Code | Route | Strength | Effective Date |
---|---|---|---|---|---|
No FDA approvals found for this drug. |
EMA Drug Approvals
Approved Product | Authorization Holder | Status | Issued Date |
---|---|---|---|
No EMA approvals found for this drug. |
HSA Drug Approvals
Approved Product | Manufacturer | Approval Number | Dosage Form | Strength | Approval Date |
---|---|---|---|---|---|
No HSA approvals found for this drug. |
NMPA Drug Approvals
Approved Product | Company | Approval Number | Drug Type | Dosage Form | Approval Date |
---|---|---|---|---|---|
Malaridine Phosphate Injection | 国药准字H33020031 | 化学药品 | 注射剂 | 3/2/2020 |
PPB Drug Approvals
Approved Product | Registration No. | Company | Licence No. | Strength | Registration Date |
---|---|---|---|---|---|
No PPB approvals found for this drug. |
TGA Drug Approvals
Approved Product | ARTG ID | Sponsor | Registration Type | Status | Registration Date |
---|---|---|---|---|---|
No TGA approvals found for this drug. |
Help Us Improve
Your feedback helps us provide better drug information and insights.